Rosenkranz Prize Winner Investigates Impact of Price Controls on Contraceptives
Natalia Serna, PhD, is this year’s Rosenkranz Prize for her research examining how price ceilings on oral contraceptives impact women’s health and their access to medicine in low- to middle-income countries, particularly those of Latin America.
QALY Ban Could Harm People with Disabilities and Chronic Illness
The U.S. House passed a bill that would ban the use of a metric known as quality-adjusted life-years (QALYs) in coverage and payment determinations for federal health-care programs. SHP's Joshua Salomon writes in this Health Affairs commentary the bill would compromise the evaluation of medical treatments.
In Conflict Zones and Borderlands, Paul Wise Protects the Health of Vulnerable Children
Stanford Health Policy's Paul Wise — professor of pediatrics and senior fellow at the Freeman Spogli Institute for International Studies — is featured in this Stanford Magazine story about his work at the U.S.-Mexico border as the federally appointed juvenile monitor and around the world as a pediatrician who works on behalf of children of conflict.
This year's Rosenkranz Prize winner is Natalia Serna, PhD, a health economist investigating how women's health is impacted by price controls on oral contraceptives.
This new study by SHP's Adrienne Sabety examines the association between prescriber workforce exit, long-term opioid treatment discontinuation, and clinical outcomes.
The U.S. House passed a bill that would ban the use of a metric known as quality-adjusted life-years (QALYs) in coverage and payment determinations for federal health-care programs. SHP's Joshua Salomon writes in this Health Affairs commentary the bill would compromise the evaluation of medical treatments.
A new study led by Stanford Health Policy researchers finds that algorithmic changes to a chronic kidney disease care equation are likely insufficient to achieve health equity as many other structural inequities remain.
Stanford Health Policy's Paul Wise — professor of pediatrics and senior fellow at the Freeman Spogli Institute for International Studies — is featured in this Stanford Magazine story about his work at the U.S.-Mexico border as the federally appointed juvenile monitor and around the world as a pediatrician who works on behalf of children of conflict.
A team of Stanford researchers has determined that patients taking GLP-1 receptors used to lower blood glucose levels may not need to take a pause before surgery.
Eliza Ennis and Selina Pi—two PhD students who are working with Stanford Health Policy faculty mentors—have been awarded National Science Foundation graduate fellowships.
The annual award from the National Institute for Health Care Management Foundation recognizes the contributions of researchers and journalists who examine new evidence that advances the health system and the health of Americans.
In a new study by members of Josh Salomon's Prevention Policy Modeling Lab, the researchers found profound racial and ethnic disparities that are stalling overall progress against TB.
The often hidden burdens of long COVID is the subject of the latest Stanford Health Policy Forum, with researchers likening it to the early days of chronic fatigue syndrom.
At the 2024 SIEPR Economic Summit, health care experts discussed solutions to a concern that 75% of Americans share: How to make medical care affordable and accessible.
It would seem like AI would be a logical tool to help evaluate insurance coverage and claims. But results so far have been sobering, leading to class-action lawsuits and congressional committees demanding answers.
A multidisciplinary team of Stanford researchers has found that relaxed guidelines for opioid use disorder during the COVID-19 pandemic were likely not only effective, but cost-effective as well.
Michelle Mello and colleagues argue that state legal reforms have exacerbated rather than improved weaknesses in U.S. emergency powers revealed by COVID-19, jeopardizing future responses.
In her testimony before the U.S. Senate Finance Committee, Mello emphasized the need for federal guardrails and standards regarding the use of artificial intelligence in health care.
